
Bausch Health Companies BHC
$ 6.8
-1.81%
Quarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies Gross Profit 2011-2025 | BHC
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 6.25 B | 6.03 B | 6.18 B | 7.06 B | 7.86 B | 6.01 B | 3.86 B | 2.51 B | 1.74 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.86 B | 1.74 B | 5.28 B |
Gross Profit of other stocks in the Drug manufacturers industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
69.9 M | - | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
86.4 M | $ 0.74 | -3.16 % | $ 52.6 M | ||
|
Aerie Pharmaceuticals
AERI
|
57.8 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
79.5 M | $ 1.68 | -3.51 % | $ 181 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-616 K | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-1.43 M | - | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
-25.8 M | $ 3.09 | -5.45 % | $ 1.63 B | ||
|
Agile Therapeutics
AGRX
|
10.6 M | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
188 M | $ 5.22 | -3.43 % | $ 86.3 M | ||
|
Catalent
CTLT
|
953 M | - | - | $ 11.5 B | ||
|
HEXO Corp.
HEXO
|
-75.7 M | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
25.4 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
135 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
1.35 B | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
318 M | $ 11.73 | 2.71 % | $ 601 M | ||
|
Evoke Pharma
EVOK
|
-63.7 K | $ 10.97 | 0.18 % | $ 36.7 M | ||
|
Athenex
ATNX
|
26.7 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
154 M | $ 21.42 | 0.28 % | $ 2.04 B | ||
|
Evolus
EOLS
|
182 M | $ 7.13 | 1.21 % | $ 442 M | ||
|
Harrow Health
HROW
|
90.6 M | $ 46.05 | -2.15 % | $ 1.5 B | ||
|
China Pharma Holdings
CPHI
|
-1.99 M | $ 1.53 | -1.92 % | $ 26.7 M | ||
|
Lannett Company
LCI
|
33.2 M | - | 1.15 % | $ 7.11 M | ||
|
Organogenesis Holdings
ORGO
|
366 M | $ 4.89 | 1.45 % | $ 644 M | ||
|
OrganiGram Holdings
OGI
|
47.5 M | $ 1.84 | -4.43 % | $ 402 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
28.8 M | $ 2.95 | 16.6 % | $ 41.5 M | ||
|
Pacira BioSciences
PCRX
|
314 M | $ 26.59 | 1.12 % | $ 1.23 B | ||
|
Rockwell Medical
RMTI
|
8.7 M | $ 0.9 | -2.76 % | $ 21 M | ||
|
PetIQ
PETQ
|
253 M | - | 1.64 % | $ 400 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
5.46 M | $ 3.44 | -4.18 % | $ 4.27 M | ||
|
Relmada Therapeutics
RLMD
|
1.09 K | $ 4.07 | 0.25 % | $ 123 M | ||
|
Jupiter Wellness
JUPW
|
-2.45 M | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
1.54 B | $ 13.0 | -1.03 % | $ 1.79 B | ||
|
ProPhase Labs
PRPH
|
70.7 M | $ 0.11 | -4.97 % | $ 1.74 M | ||
|
Radius Health
RDUS
|
221 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
48.2 M | - | -4.76 % | $ 65.3 M | ||
|
Sundial Growers
SNDL
|
240 M | $ 2.08 | -5.96 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
41.6 M | - | - | $ 1.08 B | ||
|
Veru
VERU
|
5.85 M | $ 2.46 | 1.6 % | $ 332 M | ||
|
PLx Pharma
PLXP
|
3.4 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
3.58 M | $ 0.64 | -1.5 % | $ 30.6 M | ||
|
cbdMD
YCBD
|
12 M | $ 1.55 | 28.75 % | $ 6.68 M | ||
|
Tilray
TLRY
|
147 M | $ 11.11 | -8.58 % | $ 6.87 B | ||
|
TherapeuticsMD
TXMD
|
1.3 M | $ 1.74 | -0.86 % | $ 18.2 M | ||
|
Zomedica Corp.
ZOM
|
17.3 M | - | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
6.5 B | $ 11.68 | 0.26 % | $ 14.2 B |